Qatar Foundation appoints Yousif Al-Naama as new CEO
Qatar Foundation has announced the appointment of Yousif Al-Naama as its new Chief Executive Officer (CEO) and new, expanded responsibilities for Her Excellency Sheikha Hind bint Hamad Al Thani as the organization's Vice Chairperson.
This evolution reflects how, in the year that marks its 30th anniversary, Qatar Foundation (QF) is entering a new phase of its journey, as it continues to unlock human potential and create impact and benefit for the people of Qatar, the region, and the world, across its pillars of education, science and research, and community development.
Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, said:
'Her Excellency Sheikha Hind's appointment as Chief Executive Officer of Qatar Foundation nine years ago came with a clear mandate: to enhance the Foundation's role and to ensure its continuity locally, regionally, and internationally. Sheikha Hind has excelled in her mandate, and her contributions have exceeded our expectations.'
Her Excellency Sheikha Hind said:
'In my role as the organization's Vice Chairperson – a position I have held since 2011 – I will focus on the expansion of QF's strategic role and impact, through strengthening partnerships with QF's stakeholders within Qatar and globally, elevating the organization's international profile, and advancing strategic initiatives that span QF's diverse ecosystem of knowledge.'
Mr. Al-Naama brings a wide-ranging skillset rooted in organizational planning and strategy to his role as CEO of Qatar Foundation, which he will assume on 1 June 2025. He has played an instrumental role in shaping and advancing Qatar's digital transformation within both the public and private sectors; contributed to the development of Qatar's first Information and Communications Technology Strategy and Masterplan; and was among the founding members of Qatar-based IT services provider Malomatia, serving as its CEO for over 15 years.
'I am truly honored, and immensely proud, to be asked to assume the role of Chief Executive Officer of Qatar Foundation, an organization I have always greatly admired,' said Mr. Al-Naama. 'I thank Her Highness Sheikha Moza bint Nasser and Her Excellency Sheikha Hind bint Hamad Al Thani for placing their faith in me, and I will do my utmost to repay this faith. My task is clear: to implement the vision of Her Highness, and to harness the transformative impact that QF has seen during Her Excellency's tenure as Chief Executive Officer.'
Source and cover image credit: Press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ILoveQatar.net
2 hours ago
- ILoveQatar.net
H.H. Sheikha Moza inaugurates Sidra Medicine's new Pediatric Hematopoietic Stem Cell Transplant Ward
Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development, officially inaugurated the new pediatric Hematopoietic Stem Cell Transplant (HSCT) ward at Sidra Medicine, a Qatar Foundation entity. The new ward is dedicated to treating children with blood disorders, immune system diseases, and genetic conditions. During the visit, Her Highness toured the facility, engaged with clinical teams, and received an overview of the HSCT program's role in advancing care and stem cell and gene therapies for children in Qatar and the region. Her Highness was accompanied by His Excellency Mansoor bin Ebrahim bin Saad Al Mahmoud, the Minister of Public Health, members of Sidra Medicine's Board of Directors and senior leadership, including Dr. Iyabo Tinubu-Karch, Chief Executive Officer and Prof. Ibrahim Janahi, Chief Medical Officer. The HSCT ward is a core part of Sidra Medicine's HSCT Program, using curative therapies to provide life-saving care and treatment for children with a range of blood diseases and cancers. This includes malignant and non-malignant conditions such as leukemia, lymphoma, thalassemia, sickle cell disease, immune deficiencies, and metabolic disorders. HSCT also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new pediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections - one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr. Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr. Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process. For more details about Sidra Medicine's Hematology and Oncology services and its GMP facility, please visit:
Qatar Tribune
18 hours ago
- Qatar Tribune
QF's BilAraby Summit highlights how Arabic can thrive in digital age
Tribune News Network Doha Earlier this year, Qatar Foundation's inaugural BilAraby Summit brought together innovators, entrepreneurs, and thought leaders to explore the evolution of the Arabic language in the age of Artificial Intelligence, digitization, and entrepreneurship—while honouring its cultural legacy. Held at Qatar Foundation's Education City, the summit served as a platform to amplify voices and ideas from across the Arabic-speaking world. More than 800 participants, including technology experts and creators, engaged in panel discussions, interactive workshops, and dialogue-driven sessions, focusing on the role of Arabic as a dynamic and modern language. 'This summit focused on practical models demonstrating Arabic's value as a language of science and innovation,' said Dr Anwar Dafa-Alla, translation consultant at the BilAraby Initiative. Dr Dafa-Alla participated in an exploratory session titled 'Translating BilAraby Content: A Bridge to Global Communication,' where he underlined the initiative's Open Translation Project which aims to translate Arabic content into multiple languages, extending its reach to a global audience. Dr Dafa-Alla said the project seeks to make BilAraby sessions accessible worldwide, freely disseminate knowledge, and support the digital growth of the Arabic language. It also aims to strengthen Arab identity globally, and foster social impact by sharing inspiring ideas with non-Arabic speakers. In light of the success of the inaugural summit, BilAraby is preparing for its second edition alongside a number of regional events. Faisal Alagel, chief executive producer of Sard Group from Kuwait, said: 'In recent years, we have seen a renewed focus on questions of identity and language within Arab society. This shift marks a new phase of reexamining the values that shape our lives, the language we use to think, to speak with one another and with our children, and to create arts and sciences. The BilAraby Summit offered a valuable platform for dialogue and the exchange of experiences and expertise among content creators and professionals engaged in the Arab world.' Among these compelling voices who shared their story at the summit was Abdul Rahman Sayidi from Mauritania, a business administration researcher and academic advisor, who introduced a visionary model of working that harmonizes with the rhythms of the universe and human nature. He explained that his model, which blends philosophy and science, depicts time as a facilitator of life, rather than a source of stress. The summit also spotlighted the journey of Arab innovators including Egyptian engineer Taimur Al-Hadidi, who built a house entirely using recycled materials; Diana Al-Sindi, the Iraqi engineer at the National Aeronautics and Space Administration (NASA), who inspired by distant stars, taught Arab youth that space is an adventure for all; and Jordanian educator Salam Katanani, who transformed the world of science into a realm of exploration and excitement.
Qatar Tribune
3 days ago
- Qatar Tribune
Trump to double tariffs on foreign steel to 50%
Agencies U.S. President Donald Trump is doubling the tariff on steel imports to 50%, a dramatic increase that could further push up prices for a metal used to make housing, autos and other goods.'Today, I have a major announcement,' Trump said during a rally at a U.S. Steel facility in Pittsburgh, Pennsylvania. 'We are going to be imposing a 25% increase. We're going to bring it from 25% to 50% the tariffs on steel into the United States of America, which will even further secure the steel industry in the United States, nobody's going to get around that,' Trump said. He argued that the increase would close gaps that foreign competitors have used to bypass previous tariffs. 'So, we're bringing it up from 25%, we're doubling it to 50% and that's a loophole,' he a post later on his Truth Social platform, he added that aluminum tariffs would also be doubled to 50%. He said both tariff hikes would go into effect spoke at U.S. Steel's Mon Valley Works-Irvin Plant in suburban Pittsburgh, where he also discussed a details-to-come deal under which Japan's Nippon Steel will invest in the iconic American steelmaker. Though Trump initially vowed to block the Japanese steelmaker's bid to buy Pittsburgh-based U.S. Steel, he reversed course and announced an agreement last week for 'partial ownership' by Nippon. It's unclear, though, if the deal his administration helped broker has been finalized or how ownership would be structured. Nippon Steel has never said it is backing off its bid to outright buy and control U.S. Steel as a wholly owned subsidiary, even as it increased the amount of money it promised to invest in U.S. Steel plants and gave guarantees that it wouldn't lay off workers or close plants as it sought federal approval of the acquisition. 'We're here today to celebrate a blockbuster agreement that will ensure this storied American company stays an American company,' Trump said as he opened an event at one of U.S. Steel's warehouses. 'You're going to stay an American company, you know that, right?' As for the tariffs, Trump said doubling the levies on imported steel 'will even further secure the steel industry in the U.S.' But such a dramatic increase could push prices even higher. Steel prices have climbed 16% since Trump became president in mid-January, according to the government's Producer Price Index. As of March 2025, steel cost $984 a metric ton in the United States, significantly more than the price in Europe ($690) or China ($392), according to the U.S. Commerce Department. The United States produced about three times more steel than it imported last year, with Canada, Brazil, Mexico and South Korea being the largest sources of steel imports. Analysts have credited tariffs going back to Trump's first term with helping strengthen the domestic steel industry, something that Nippon Steel wanted to capitalize on in its offer to buy U.S. Steel. The United Steelworkers union remained skeptical. Its president, David McCall, said in a statement that the union is most concerned 'with the impact that this merger of U.S. Steel into a foreign competitor will have on national security, our members and the communities where we live and work.' Trump stressed the deal would maintain American control of the storied company, which is seen as both a political symbol and an important matter for the country's supply chain, industries like auto manufacturing and national security. Trump, who has been eager to strike deals and announce new investments in the U.S. since retaking the White House, is also trying to satisfy voters, including blue-collar workers, who elected him as he called to protect U.S. manufacturing. U.S. Steel has not publicly communicated any details of a revamped deal to investors. Nippon Steel issued a statement approving of the proposed 'partnership' but also has not disclosed terms. State and federal lawmakers who have been briefed on the matter describe a deal in which Nippon will buy U.S. Steel and spend billions on U.S. Steel facilities in Pennsylvania, Indiana, Alabama, Arkansas and Minnesota. The company would be overseen by an executive suite and board made up mostly of Americans and protected by the U.S. government's veto power in the form of a 'golden share.' Unionized steelworkers said there is some split opinion in the ranks over Nippon Steel's acquisition, but that sentiment has shifted over time as they became more convinced that U.S. Steel would eventually shut down their Pittsburgh-area plants.
